MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

3.32 0.61

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.25

Max

3.39

Belangrijke statistieken

By Trading Economics

Inkomsten

-17M

-70M

Verkoop

547K

47M

Winstmarge

-147.345

Werknemers

560

EBITDA

-17M

-66M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+49.68% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

389M

1.1B

Vorige openingsprijs

2.71

Vorige sluitingsprijs

3.32

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 okt 2025, 20:45 UTC

Winsten

Costco Wholesale Sales Climb in September, Early October

8 okt 2025, 20:12 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 okt 2025, 16:39 UTC

Belangrijke Marktbewegers

Mining Shares Rise as Gold Prices Soar

8 okt 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

8 okt 2025, 23:43 UTC

Marktinformatie

Gold Falls on Possible Profit-Taking -- Market Talk

8 okt 2025, 23:18 UTC

Acquisities, Fusies, Overnames

JD Logistics to Finance Acquisition Using Internal Funds

8 okt 2025, 23:17 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 okt 2025, 23:16 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 okt 2025, 21:54 UTC

Marktinformatie
Winsten

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 okt 2025, 21:30 UTC

Marktinformatie

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 okt 2025, 21:26 UTC

Marktinformatie
Winsten

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 19:15 UTC

Marktinformatie

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 okt 2025, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 okt 2025, 18:47 UTC

Marktinformatie

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Will Remain a Publicly Traded Co >TASK

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 okt 2025, 18:07 UTC

Marktinformatie

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 okt 2025, 15:57 UTC

Marktinformatie

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 okt 2025, 15:56 UTC

Marktinformatie

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 okt 2025, 15:53 UTC

Marktinformatie

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 okt 2025, 15:43 UTC

Acquisities, Fusies, Overnames

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 okt 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

49.68% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.67 USD  49.68%

Hoogste 5 USD

Laagste 4 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat